Next report date
Report period
H1 2024
EPS estimate
0.01EUR
Revenue estimate
1.97 BEUR
0.0145EUR
269.18 MEUR
3.36 BEUR
9.67 B
About SINO BIOPHARMACEUTICAL
Sector
CEO
S Y Tse
Headquarters
Hong Kong
Website
Employees (FY)
25.81 K
Founded
2000
FIGI
BBG000CBMMF2
Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.
#1177 Good Support at $6.18 LevelHi Everybody
#1177 shows good support at $6.18 Level since July, it aims for the BLUE LINES, and stop if close below the RED Line.
LONG 1177Expecting bounce from extremely oversold weekly and daily levels. If stop breached, be prepared to catch new daily reversal on lower levels with a tight stop.
Double three of lesser degree formation possibleThe wave theory suggests HKEX:1177 that the prolong flat correction will be prolonged at least for the midterm period
Sino Biopharma- Double three in action. HKEX:1177
Current wave analysis suggests that the stock has already completed a regular flat and zig-zag action.
Price action suggest that the stock is heading for further downside correction as rising wedge formation gave some hint that the stock is losing its steam on bullish momentum.
Thursda
1177, Sino Biopharm - Trailing Stop and Ascending TriangleHKEX:1177
After our long entry on the head and shoulders of reversing, we are managing the position by gradually moving the stop profits below the last lows.
Currently an upward triangle is forming within our trailing stop, which if it broke the resistance level would probably further give a bullis
1177, Sino Biopharm - Trailing Stop after Breakingout on H&SHKEX:1177
Here too we continue to move the stop loss in trailing stop mode, until we reach our primary objective, that is Break Even Point, equal to the entry point plus commissions.
Remember that Risk Management and Position Sizing are the fundamental points to have a positive trading operation.
S
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SMZ1 is 0.3188 EUR — it has increased by 1.56% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange SINO BIOPHARMACEUTICAL LTD. stocks are traded under the ticker SMZ1.
SINO BIOPHARMACEUTICAL LTD. is going to release the next earnings report on Aug 29, 2024. Keep track of upcoming events with our Earnings Calendar.
SMZ1 stock is 3.67% volatile and has beta coefficient of 1.52. Check out the list of the most volatile stocks — is SINO BIOPHARMACEUTICAL LTD. there?
SMZ1 earnings for the last quarter are 0.01 EUR per share, whereas the estimation was 0.01 EUR resulting in a 13.71% surprise. The estimated earnings for the next quarter are 0.01 EUR per share. See more details about SINO BIOPHARMACEUTICAL LTD. earnings.
SINO BIOPHARMACEUTICAL LTD. revenue for the last quarter amounts to 1.93 B EUR despite the estimated figure of 1.94 B EUR. In the next quarter revenue is expected to reach 1.90 B EUR.
Yes, you can track SINO BIOPHARMACEUTICAL LTD. financials in yearly and quarterly reports right on TradingView.
SMZ1 stock has risen by 17.21% compared to the previous week, the month change is a 4.67% fall, over the last year SINO BIOPHARMACEUTICAL LTD. has showed a 34.74% decrease.
SMZ1 net income for the last quarter is 105.42 M EUR, while the quarter before that showed 166.50 M EUR of net income which accounts for −36.68% change. Track more SINO BIOPHARMACEUTICAL LTD. financial stats to get the full picture.
Today SINO BIOPHARMACEUTICAL LTD. has the market capitalization of 6.07 B, it has decreased by 0.36% over the last week.
SINO BIOPHARMACEUTICAL LTD. dividend yield was 1.44% in 2023, and payout ratio reached 39.94%. The year before the numbers were 2.63% and 75.57% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, SMZ1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SINO BIOPHARMACEUTICAL LTD. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 25.81 K employees. See our rating of the largest employees — is SINO BIOPHARMACEUTICAL LTD. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SINO BIOPHARMACEUTICAL LTD. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SINO BIOPHARMACEUTICAL LTD. stock shows the sell signal. See more of SINO BIOPHARMACEUTICAL LTD. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SINO BIOPHARMACEUTICAL LTD. future price: according to them, SMZ1 price has a max estimate of 0.82 EUR and a min estimate of 0.36 EUR. Read a more detailed SINO BIOPHARMACEUTICAL LTD. forecast: see what analysts think of SINO BIOPHARMACEUTICAL LTD. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SINO BIOPHARMACEUTICAL LTD. EBITDA is 871.95 M EUR, and current EBITDA margin is 25.87%. See more stats in SINO BIOPHARMACEUTICAL LTD. financial statements.